Crux Wealth Advisors Takes $1.30 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

Crux Wealth Advisors purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,623 shares of the medical research company's stock, valued at approximately $1,301,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Synergy Asset Management LLC acquired a new position in shares of IQVIA during the 4th quarter valued at $33,000. Lee Danner & Bass Inc. bought a new stake in IQVIA in the fourth quarter worth about $44,000. Zions Bancorporation N.A. boosted its position in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after purchasing an additional 85 shares in the last quarter. Versant Capital Management Inc grew its stake in shares of IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock worth $58,000 after purchasing an additional 93 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new stake in shares of IQVIA in the 4th quarter worth approximately $60,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Performance

IQV traded down $3.63 on Thursday, hitting $144.82. The company had a trading volume of 1,686,773 shares, compared to its average volume of 1,395,904. The stock has a market cap of $25.53 billion, a price-to-earnings ratio of 19.34, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company's fifty day moving average price is $178.83 and its 200 day moving average price is $198.11. IQVIA Holdings Inc. has a 1-year low of $135.97 and a 1-year high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on IQV shares. Truist Financial cut their price objective on IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research report on Thursday, April 10th. Citigroup dropped their price target on IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Stifel Nicolaus reduced their price objective on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a research note on Friday, February 7th. StockNews.com downgraded shares of IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 18th. Six research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, IQVIA presently has an average rating of "Moderate Buy" and an average price target of $241.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.